First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial [...] (Q33408270)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial [...] |
scientific article |
Statements
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group (English)
Reyes Arranz
Ana García-Noblejas
Carlos Grande
Jimena Cannata-Ortiz
José J Sánchez
José-Antonio García-Marco
Concepción Aláez
Javier Pérez-Calvo
Pilar Martínez-Sánchez
Blanca Sánchez-González
Miguel-Angel Canales
Eulogio Conde
Alejandro Martín
Eva Arranz
Dolores Caballero
1 reference